Front-line immunosuppressive treatment of acquired aplastic anemia (Q38061040)

28 August 2017

1 reference

title

Front-line immunosuppressive treatment of acquired aplastic anemia (English)

1 reference

28 August 2017

C Dufour

1

1 reference

28 August 2017

J Svahn

series ordinal

2

1 reference

28 August 2017

A Bacigalupo

series ordinal

3

1 reference

28 August 2017

Severe Aplastic Anemia–Working Party of the EBMT

series ordinal

4

1 reference

28 August 2017

language of work or name

English

0 references

publication date

19 November 2012

1 reference

Bone Marrow Transplantation

28 August 2017

published in

1 reference

28 August 2017

volume

48

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

174-177

1 reference

Guidelines for the diagnosis and management of aplastic anaemia

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.222

Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.222

Horse versus rabbit antithymocyte globulin in acquired aplastic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.222

Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.222

Cyclosporin A response and dependence in children with acquired aplastic anaemia: a multicentre retrospective study with long-term observation follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.222

A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.222

Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.222

Tacrolimus as an alternative to cyclosporine in the maintenance phase of immunosuppressive therapy for severe aplastic anemia in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.222

Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.222

Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.222

Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.222

High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.222

Eltrombopag and improved hematopoiesis in refractory aplastic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.222

Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.222

Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapiant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.222

7 January 2021

Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.222

7 January 2021

Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia: a single-center retrospective study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.222

7 January 2021

Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.222

7 January 2021

Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.222

7 January 2021

Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.222

7 January 2021

Identifiers

DOI

10.1038/BMT.2012.222

1 reference

Dimensions Publication ID

28 August 2017

1031407712

0 references

1 reference